{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:21:44Z","timestamp":1791685304082,"version":"4.3.4"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The First-in-Human clinical trial of a novel magnetic nanoparticle-based hyperthermia therapy consisting of iron oxide multicore encapsulated nanoparticles, termed Sarah Nanoparticles (SaNP), administered intravenously before being exposed to alternating magnetic field (AMF) irradiation began enrolment. We report the preliminary results on two patients with advanced primary liver cancer; a 75-year-old man with advanced stage hepatocellular carcinoma and a 69-year-old woman with metastatic cholangiocarcinoma treated with a SaNP dose of 1.8 mg\/kg followed by pulsed AMF irradiation for a total duration of 15 min. Toxicity assessment was performed using standard criteria for the grading of adverse events during treatment and after a follow-up period of 30 days. Tumor response was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Both patients tolerated the procedure well without any significant clinical or laboratory toxicities. Magnetic resonance imaging (MRI) analysis revealed accumulation of the SaNP in the tumors followed by clearance from the liver and spleen on T2*-weighted MR imaging. Tumor response as assessed by RECIST 1.1 demonstrated stable disease at the follow-up timepoint. Preliminary analysis of this First-in-Human trial of magnetic nanoparticle-based hyperthermia treatment for patients with advanced cancer demonstrated encouraging results both in terms of efficacy by halting disease progression and toxicity, where no significant side effects occurred.<\/jats:p>","DOI":"10.3389\/fonc.2025.1742249","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:04:02Z","timestamp":1768482242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Treatment with magnetic nanoparticle-based hyperthermia stabilizes metastatic disease in stage IV primary liver cancer patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Sarah","family":"Kraus","sequence":"first","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir","family":"Arbib","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Ventura-Bixenshpaner","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pazit","family":"Rukenstein","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirav","family":"Hirsh-Kovacs","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Shalev","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Eltanani","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi","family":"Ron","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gumina","sequence":"additional","affiliation":[{"name":"Department of Radiology, Meir Medical Centre","place":["Kfar Saba, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shalev","sequence":"additional","affiliation":[{"name":"New Phase Ltd.","place":["Petah Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Geschwind","sequence":"additional","affiliation":[{"name":"Oncology, Image-Guided Therapy, and Imaging Core Lab, North American Science Associates (NAMSA)","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.rpor.2013.09.011","article-title":"Magnetic nanoparticle-based hyperthermia for cancer treatment","volume":"18","author":"Ba\u00f1obre-L\u00f3pez","year":"2013","journal-title":"Rep Pract Oncol Radiother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2022.04.045","article-title":"Nanomaterials in cancer: reviewing the combination of hyperthermia and triggered chemotherapy","volume":"347","author":"Ribeiro","year":"2022","journal-title":"J Control Release"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25122874","article-title":"Magnetic hyperthermia for cancer treatment: main parameters affecting the outcome of in vitro and in vivo studies","volume":"25","author":"Vilas-Boas","year":"2020","journal-title":"Molecules"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/nano11051203","article-title":"Fundamentals to apply magnetic nanoparticles for hyperthermia therapy","volume":"11","author":"Fatima","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/acsanm.1c02676","article-title":"Fe3O4 nanoparticles and paraffin wax as phase change materials embedded in polymer matrixes for temperature-controlled magnetic hyperthermia","volume":"4","author":"Cohen-Erner","year":"2021","journal-title":"ACS Appl Nano Mater"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.37421\/2165-7920.2024.14.1596","article-title":"Tumor necrosis in a breast cancer case as a result of a novel systemic magnetic nanoparticle hyperthermia \u201cFirst in-Human\u201d safety and feasibility trial","volume":"14","author":"Kraus","year":"2024","journal-title":"J Clin Case Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.29011\/2574-710X.10304","article-title":"Extended treatment of magnetic nanoparticle hyperthermia in a \u201cFirst-in-Human\u201d trial demonstrates safety and feasibility in an advanced cervical cancer case","volume":"10","author":"Arbib","year":"2025","journal-title":"J Oncol Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.761045","article-title":"Novel nanoparticle-based cancer treatment effectively inhibits lung metastases and improves survival in a murine breast cancer model","volume":"11","author":"Kraus","year":"2021","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-022-03314-1","article-title":"Self-regulating novel iron oxide nanoparticle-based magnetic hyperthermia in swine: biocompatibility, biodistribution, and safety assessments","volume":"96","author":"Kraus","year":"2022","journal-title":"Arch Toxicol"},{"key":"B10","article-title":"Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","year":"2005"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.86467","article-title":"Magnetic resonance imaging and iron-oxide nanoparticles in the era of personalized medicine","volume":"7","author":"Rahman","year":"2023","journal-title":"Nanotheranostics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030621","article-title":"A validated methodological approach to prove the safety of clinical electromagnetic induction systems in magnetic hyperthermia","volume":"16","author":"Rouni","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/nano11020556","article-title":"Improvement of magnetic particle hyperthermia: healthy tissues sparing by reduction in eddy currents","volume":"11","author":"Balousis","year":"2021","journal-title":"Nanomaterials"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2021.1899310","article-title":"Mitigation of magnetic particle hyperthermia side effects by magnetic field controls","volume":"38","author":"Tsiapla","year":"2021","journal-title":"Int J Hyperthermia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1742249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:56:16Z","timestamp":1771916176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1742249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":14,"alternative-id":["10.3389\/fonc.2025.1742249"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1742249","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1742249"}}